What's on at Eureka Report this week

It's our first full week of your new era Eureka Report... and it's a lively one.

It’s our first full working week of your new era Eureka Report and we’ve picked a lively week to get started.

In case you missed it Eureka Interactive hosted our first ‘live’ Inside Line today and we did a special edition on the Greek crisis. If you click here or watch the webcast embedded in our lead story this evening from Adam Carr you can see the event. Alan Kohler and I also had stockbroker Marcus Padley in the studio as a special guest.

To fill you in on the upcoming events for the week ahead: Tomorrow (Tuesday) at 12.30 I will be back in the studio, this time for a live webcast with our head of research Simon Dumaresq. Simon will be discussing and taking questions from subscribers about his small cap model portfolio which we premiered on the site last week.

Alan Kohler picks up the pace mid-week: At 10.30am on Wednesday he will be interviewing the CEO of Empired Ltd, Russell Baskerville. Empired is one of our favoured stocks at Eureka and it currently represents about 7 per cent of our small cap portfolio.

On Thursday at 11am Alan will interview Nigel Finch, the chairman of 3D Medical.

Then to round out the week, one of Eureka’s all-time popular contributors, John Abernethy of Clime, will be in the studio to talk with Mitchell Sneddon, our Listed Investment Company specialist. Mitchell recently interviewed fund manager Geoff Wilson about his very ambitious plan to raise up to $550 million for an offshore equities LIC which is designed to support a number of charities - you can watch it here.

Of course until a few weeks ago John was Mitchell’s boss at Clime! So there should be some interesting questions about LICs and everything else in the investment world.

In Eureka Report editorial tonight we will be skipping an edition of Collected Wisdom but it will return to these pages next Monday July 13. 

All these events are live and every event is open to you – the Eureka Report subscriber. There's a full schedule here. We hope you like it, we’re enjoying it immensely.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles